Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12358928-B2

Patent

Publication Date

2025-07-15

Expiration Date


Abstract

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Core Innovation

The description defines heterocyclic compound series, including Formulas I through VI, alongside characterized bicyclic lactam-heteroaryl carboxamides coupled to oxazepinone, azepinone, or cyclopropane-fused scaffolds as receptor-interacting protein kinase 1 inhibitors. Disclosed embodiments encompass stereoisomers, tautomers, prodrugs, and pharmaceutically acceptable salts, with synthetic routes including [procedural detail omitted for safety]. Independent claim coverage specifically designates compounds chosen from depicted structures 38A, 38B, and 200, alongside a compound possessing a recited chemical structure.

The description reports biological assay data demonstrating receptor-interacting protein kinase 1 binding, kinase inhibition, and cellular activity, with compounds 38A and 200 exhibiting activity across all three measures. Reported evaluations show distinct blood-brain barrier properties, hepatic clearance, and MDCKII-MDR1 efflux ratios, while Compound 42 demonstrates in vivo activity in a TNF/zVAD mouse model. The compounds provide targeted inhibition for inflammatory, autoimmune, degenerative, necrotic, ocular, infectious, malignant, and ischemic disorders.

Claims Coverage

The claims identify two independent claims defining two inventive features directed to specified chemical compound structures and their designated derivative forms.

Compounds selected from depicted structures 38A, 38B, and 200

Claim 1 covers a compound chosen from depicted structures 38A, 38B, and 200, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or mixture of stereoisomers thereof.

Compound having the recited structure

Claim 3 covers a compound having the recited structure, or a tautomer, stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof.

The two independent claims encompass the specified depicted chemical compounds and a compound having the recited structure, including stated tautomers, stereoisomers, stereoisomer mixtures, and pharmaceutically acceptable salts.

Stated Advantages

Compound 42 shows lower human hepatocyte clearance than comparative Example A, supporting improved metabolic stability and potential for lower or less frequent dosing.

In the TNF/zVAD mouse model, oral Compound 42 inhibits temperature loss at a lower reported dose than the cited comparator.

Documented Applications

Pharmaceutical compositions comprising a claimed compound or specified form together with a pharmaceutically acceptable excipient, including routes of administration, dosing ranges, and combination therapies.

Therapeutic use as RIPK1 inhibitors for inflammatory, autoimmune, degenerative, necrotic, ocular, infectious, malignant, ischemic, and cell-death-related disorders, including inflammatory bowel disease, rheumatoid arthritis, neurodegenerative diseases, and ischemic injury.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.